uniQure CEO Defends Huntington’s Therapy Data, Sees Opportunity Ahead of FDA Decision
uniQure (NASDAQ:QURE) Chief Executive Matt Kapusta said investors are focused on regulatory risk surrounding its experimental Huntington’s disease therapy, AMT-130, but may be underestimating the need for treatment and the potential commercial opportunity. Speaking at Guggenheim’s 3rd Annual Healthcare Innovation Conference, Kapusta said the company plans to discuss its commercial strategy further as it approaches […]
17 Nov 02:44 · The Markets Daily